Skip to main content
OpenTrials
Completed

NCT Number: NCT05323448

Efficacy of ARISTA-AH for Restoring Hemostasis Following Posterior Long-segment Spinal Fusion.

The aim of this study is to assess the efficacy of the ARISTA AH for restoring hemostasis following a long segment posterior spinal fusion.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Polyclinique Bordeaux Nord Aquitaine

Bordeaux, 33077, France

About this study

After being informed about the study and potential risks, all patients giving written inform consent will be included in the study during their preoperative visit. After eligibility criteria checking and based on their respective surgical indication, participants will be randomized in a single-blinded and stratified manner (participant only) in a 1:1 ratio to ARISTA-AH or no ARISTA-AH. The stratification process will consider the number of instrumented vertebra during each surgery (level 1: 5 to 8 vertebra; level 2: 9 or more instrumented vertebra).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient eligible to a posterior lumbar or thoraco-lumbar long-segment spinal fusion.
  • Surgery targeting at least 5 adjacent vertebra combined with one of the following procedure:
  • Intersomatic bone graft;
  • Pedicle substraction osteotomy;
  • Any other intervertebral osteotomy (e.g. Smith-Petersen osteotomy);
  • The use of a surgical drain inserted at the operative site is mandatory (suction drain and other drain are eligible);

Exclusion criteria

  • Subject under the age of 18 years old;
  • Subject with a known haemostatic disorder;
  • Subject with any infection or any immune system disorder;
  • Subject not eligible to a posterior spinal surgery;
  • Subject with a known allergy or any contraindication to the use of the study device;
  • Currently pregnant or planning pregnancy;
  • Prisoner or a ward of the state;
  • Subject no willing to participate in the study;
  • Subject not affiliated to a social security insurance.

Treatment and study plan

Control group

Device

During the surgical procedure, hemostasis will be achieved using the standard of care (electrocautery, pressure, ligature or any hemostatic agent).

ARISTA

Device

During the surgical procedure, hemostasis will be achieved using the standard of care (electrocautery, pressure, ligature or any hemostatic agent). Before surgical wound closure, the corresponding amount of ARISTA-AH will be applied to completely cover the bleeding site :

  • 5g for 5 to 8 instrumented vertebra
  • 10g fo 9 or more instrumented vertebra

Primary outcomes

  1. Blood loss within the first 24 hours after posterior spinal fusion

    Time frame: 24 hours

    Blood loss calculated in ml per number of instrumented vertebra

Secondary outcomes

  1. Blood loss within the first 6 hours after posterior spinal fusion

    Time frame: 6 hours

    Blood loss calculated in ml per number of instrumented vertebra

  2. Blood loss within the first 48 hours after posterior spinal fusion

    Time frame: 48 hours

    Blood loss calculated in ml per number of instrumented vertebra

  3. Total post-operative blood loss

    Time frame: 3 Days

    Cumulative blood loss observed until surgical drain removal

  4. Estimated Blodd Loss (EBL)

    Time frame: 7 Days

    EBL are calculated by multiplying the perioperative difference of haemoglobin EHb (formula used: EHb = (Hb preop - Hb post-op)/Hb preop) by the patient's estimated blood volume (EBV = weight x F; F = 75 for adult males; F = 70 for adolescent males; F = 60 for females).

    EBL = EHb x EBV

  5. Hidden Blood Loss (HBL)

    Time frame: 7 Days

    HBL is the difference of the estimated blood loss (EBL) with the amount of perioperative blood loss and the amount of transfusions:

    HBL = EBL - intraoperative blood loss + transfusion

  6. Drain removal

    Time frame: 7 Days

    Delay between the date of initial surgery and the date of surgical drain removal

  7. Detection of any early post-operative haematoma

    Time frame: 7 Days

    Every participant will have an early postoperative MRI (before hospital discharge) to detect the presence of any haematoma.

    The presence (yes/no), the size (cm2) and the gravity (symptomatic, asymptomatic) of the observed haematoma will be compared between the 2 groups

  8. Improvement of back and leg pains at 3 months compared to preoperative scores

    Time frame: 3 months

    Back and leg pain intensity self-report will be assessed before and after initial procedure for each patient (at 3 months) using a 0 to 10 visual analog scale (0: no pain ; 10: most imaginable pain).

  9. Assessment of the Oswestry Disability Index

    Time frame: 3 months

    Change from baseline in self reported Oswestry Disability Index (ODI) score at 3 months.

  10. Change in Patient's quality of life

    Time frame: 3 months

    Change from baseline in self reported 12-Item Short Form Survey (SF-12) score at 3 months.

  11. Length of stay

    Time frame: 7 Days

    Length of stay is the delay between the date of admission and the date of discharge for each patient.

  12. Detection of any haemostasis disorder

    Time frame: 3 Months

    Proportion of subjects with any of the following complications related to haemostasis condition: delay or healing disorders, post-operative wound infection, neurological disorders, surgical disorders or any other complication directly related to haemostasis dysfunction or the use of ARISTA-AH product.

  13. Incidence of any serious adverse events

    Time frame: 3 Months

    Record of any intra and postoperative complications

Sponsors and collaborators

Lead sponsor

Polyclinique Bordeaux Nord Aquitaine

Other

Collaborators

  • Bard Ltd

Registry information

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Apr 12, 2022
Registry last updated
Apr 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.